Companies Target Review Aimed at Molecular Oncology and Hereditary
Diseases
SAN DIEGO--(BUSINESS WIRE)--Jan. 4, 2018--
Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS)
today announced an agreement to jointly develop novel oncology and
hereditary disease testing applications utilizing Illumina’s
next-generation sequencing (NGS) technology. The collaboration is a
significant step toward China Food and Drug Administration (CFDA) review
and approval, and serves as a starting point to deliver precision
medicine to patients throughout China.
Under the agreement, Illumina and KingMed Diagnostics will partner to
co-develop an integrated NGS system that provides cost-effective and
ready-to-use in-vitro diagnostic (IVD) assays for molecular oncology and
hereditary cancer testing. The new system is based on Illumina’s MiniSeq
System and related sequencing consumables, integrated with KingMed
Diagnostics’ proprietary testing components, which include library
preparation kits and analysis software.
The integrated system can reach cancer patients across China via KingMed
Diagnostics’ extensive clinical network that serves more than 8,000
Class 2 and Class 3B hospitals.
“KingMed Diagnostics’ motivation is to improve diagnosis and treatment
for the more than 4 million new cancer patients identified in China each
year. Our mission is to bring state-of-the-art technology to Chinese
patients by enhancing their standard of care and improving their
outcomes,” said Professor Yaoming Liang, Chairman and CEO of KingMed
Diagnostics. “Illumina is the ideal collaborator because they have a
proven track record of working with multiple domestic companies in
China, in addition to being the first company with a U.S. FDA-cleared,
next-generation sequencing instrument.”
“KingMed Diagnostics is one of the leading independent clinical
laboratory service providers in China, and as such, we are excited to
partner with them to help customize the MiniSeq System under CFDA
requirements for clinical oncology applications,” said Garret Hampton,
Ph.D., Executive Vice President of Clinical Genomics at Illumina.
“This agreement is a clear demonstration of our commitment to working
with broader clinical testing service providers in China who want to
develop and commercialize IVDs based on NGS,” said Ruilin Zhao, Ph.D.,
Illumina’s Vice President and General Manager of Greater China. “As we
continue to expand our clinical partner networks, we are focused on
providing the best healthcare solutions to patients throughout China.”
About KingMed Diagnostics
Guangzhou KingMed Diagnostics Group Co., Ltd. (www.kingmed.com.cn)
was established in 2003 as the leading independent clinical testing
laboratory in China that has been serving over 21,000 medical
institutions as our customers. KingMed develops and commercializes an
extensive medical, pathological and genomic testing offering with over
2,400 testing items to a wide range of medical and healthcare
institutions with its 37 established testing laboratories across China.
KingMed made a successful IPO at Shanghai Stock Exchange in 2017.
About Illumina
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and
uncertainties. These forward-looking statements are based on our
expectations as of the date of this release and may differ materially
from actual future events or results. Among the important factors that
could cause actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop and
commercialize our instruments and consumables, and to deploy new
products such as the MiniSeq instrument, services and applications, and
expand the markets for our technology platforms; (ii) our ability to
manufacture robust instrumentation and consumables; (iii) our ability to
successfully identify and integrate acquired technologies, products or
businesses; (iv) the future conduct and growth of the business and the
markets in which we operate; and (v) challenges inherent in developing,
manufacturing, and launching new products and services, together with
other factors detailed in our filings with the Securities and Exchange
Commission, including our most recent filings on Forms 10-K and 10-Q, or
in information disclosed in public conference calls, the date and time
of which are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or confirm
analysts’ expectations, or to provide interim reports or updates on the
progress of the current quarter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005331/en/
Source: Illumina, Inc.
Illumina
Lisa Warshaw, 323-360-8778
pr@illumina.com
or
KingMed
Diagnostics
JinJu Zhang, +8620-22283222-6142
zb-zhangjinju@kingmed.com.cn